AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

Trial Profile

AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AIPAC
  • Sponsors Immutep
  • Most Recent Events

    • 19 Jun 2018 According to an Immutep Limited media release, study is expected to be fully recruited with 226 patients by the end of 2018, with first PFS data expected in 2019.
    • 19 Jun 2018 According to an Immutep Limited media release, a total of 113 patients have been enrolled , representing half of the 226 patients planned for the study.
    • 12 Jun 2018 According to trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, the safety run-in stage (stage 1) has been completed in 2016 and the randomized part (stage 2) is recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top